162 related articles for article (PubMed ID: 16597196)
1. Identification of anti-infective targets through comparative proteomics.
Burchmore R
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):163-5. PubMed ID: 16597196
[No Abstract] [Full Text] [Related]
2. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets.
Bodovitz S; Joos T
Trends Biotechnol; 2004 Jan; 22(1):4-7. PubMed ID: 14690616
[No Abstract] [Full Text] [Related]
3. Application of LC/MS to proteomics studies: current status and future prospects.
Chen G; Pramanik BN
Drug Discov Today; 2009 May; 14(9-10):465-71. PubMed ID: 19429505
[TBL] [Abstract][Full Text] [Related]
4. The Fourth International Peptide Symposium: discovery to drugs: the peptide pipeline.
Benson H; Toth I
Biopolymers; 2008; 90(5):588. PubMed ID: 18821571
[No Abstract] [Full Text] [Related]
5. Drug resistance: a growing problem.
Peet NP
Drug Discov Today; 2010 Aug; 15(15-16):583-6. PubMed ID: 20434584
[No Abstract] [Full Text] [Related]
6. Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases.
Nagy E; Giefing C; von Gabain A
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):21-30. PubMed ID: 18251661
[TBL] [Abstract][Full Text] [Related]
7. [Anti-infectious treatment in gynecological diseases and in obstetrics].
Müller H
Dtsch Med J; 1972 Apr; 23(4):310-4. PubMed ID: 5044188
[No Abstract] [Full Text] [Related]
8. Protein-misfolding diseases and the paradigm of proteomics-based therapeutic targets.
Singh OV
Expert Rev Proteomics; 2010 Aug; 7(4):463-4. PubMed ID: 20653501
[No Abstract] [Full Text] [Related]
9. Inhibitex, Inc: antibody anti-infectives.
McCarthy AA
Chem Biol; 2005 Mar; 12(3):257-9. PubMed ID: 15797206
[No Abstract] [Full Text] [Related]
10. Clinical proteomics--on the long way from bench to bedside?
Müller GA; Müller CA; Dihazi H
Nephrol Dial Transplant; 2007 May; 22(5):1297-300. PubMed ID: 17299005
[No Abstract] [Full Text] [Related]
11. Schistosomes--proteomics studies for potential novel vaccines and drug targets.
DeMarco R; Verjovski-Almeida S
Drug Discov Today; 2009 May; 14(9-10):472-8. PubMed ID: 19429506
[TBL] [Abstract][Full Text] [Related]
12. Programmable biomaterials for dynamic and responsive drug delivery.
Stejskalová A; Kiani MT; Almquist BD
Exp Biol Med (Maywood); 2016 May; 241(10):1127-37. PubMed ID: 27190245
[TBL] [Abstract][Full Text] [Related]
13. Protein-binding microarrays: probing disease markers at the interface of proteomics and genomics.
Kerschgens J; Egener-Kuhn T; Mermod N
Trends Mol Med; 2009 Aug; 15(8):352-8. PubMed ID: 19665433
[TBL] [Abstract][Full Text] [Related]
14. The use of proteomics to study infectious diseases.
List EO; Berryman DE; Bower B; Sackmann-Sala L; Gosney E; Ding J; Okada S; Kopchick JJ
Infect Disord Drug Targets; 2008 Mar; 8(1):31-45. PubMed ID: 18473905
[TBL] [Abstract][Full Text] [Related]
15. Infectious disorders drug targets--an arsenal of knowledge on pathogen targets.
Tekwani BL
Infect Disord Drug Targets; 2008 Mar; 8(1):46-7. PubMed ID: 18473906
[No Abstract] [Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring for Anti-infective Agents in Pediatrics: The Way Forward.
Ritz N; Bielicki J; Pfister M; van den Anker J
Pediatr Infect Dis J; 2016 May; 35(5):570-2. PubMed ID: 26862676
[No Abstract] [Full Text] [Related]
18. Application of proteomics in biotechnology--microbial proteomics.
Josic D; Kovac S
Biotechnol J; 2008 Apr; 3(4):496-509. PubMed ID: 18320565
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic medicine and infection control.
Wainwright M
J Antimicrob Chemother; 2012 Apr; 67(4):787-8. PubMed ID: 22232515
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial stewardship: impact and challenges.
Hadley S
Clin Ther; 2013 Jun; 35(6):748-50. PubMed ID: 23795572
[No Abstract] [Full Text] [Related]
[Next] [New Search]
